Longitude Capital closes second life sciences fund with $385M

Friday, October 12, 2012 12:13 PM

Longitude Capital has closed the Longitude Venture Partners II, a $385 million venture capital fund dedicated to investments in drug development and medical technology. 

The Fund, which exceeded its target of $325 million, is the successor to Longitude's inaugural investment vehicle, Longitude Venture Partners, which closed in July 2008 at $325 million and exceeded its target of $250 million. The first fund has invested in nearly 20 companies including Amarin, Aptus Endosystems, AqueSys, CardioDx, Civitas Therapeutics, Corcept Therapeutics, Jazz Pharmaceuticals and NxStage Medical.

"Longitude's venture growth strategy in life sciences focuses on building balanced portfolios of primarily mid-stage to commercial-stage companies with clinically de-risked assets and three-to-five year liquidity horizons,” said Juliet Tammenoms Bakker, co-founder and managing director, Longitude. “Our approach has enabled strong absolute and relative performance driven by multiple near-term realizations across our portfolio.  We appreciate the strong support from our existing institutional and individual investors, and are delighted to welcome several new top tier institutional investors into this Fund."

Patrick Enright, Longitude co-founder and managing director, added, "We believe that Longitude Capital's investment strategy is well-suited to current market conditions. In the evolving venture capital market, our experience with PIPEs, spin-outs and recapitalizations, combined with our proactive research to identify contrarian opportunities and 'special situations' helps us exploit value dislocations and accelerate returns."

Probitas Partners acted as exclusive placement agent and financial advisor to Longitude Capital in connection with the offering. 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 21

As job growth in drug development sector soars, more employees are seeking new opportunities

U.K. study: Prisoners should have the right to participatein clinical trials on moral grounds, for healthcare access

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs